Mouse Genome Informatics
cn
    Bap1tm1.1Geno/Bap1tm1.1Geno
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+

involves: C57BL/6 * C57BL/6NTac
Key:
phenotype observed in females WTSI Wellcome Trust Sanger Institute
phenotype observed in males EuPh Europhenome
N normal phenotype
       
tumorigenesis
• changes in leukocyte numbers are consistent with a chronic myelomonocytic leukemia (CMML)-like disease
• transplantation of bone marrow cells into lethally irradiated congenic wild-type mice followed by tamoxifen treatment also results in a CMML-like disease

hematopoietic system
• at 4 weeks after the last tamoxifen injection peripheral blood shows cytological features consistent with ineffective erythropoiesis
• signs of erythroid dysplasia after tamoxifen treatment
• prominent basophilic stippling after tamoxifen treatment
• after tamoxifen treatment
• develop severe progressive anemia after tamoxifen treatment
• after tamoxifen treatment
• elevated total leukocyte numbers at 4 weeks after the last tamoxifen injection
• 4 weeks after the last tamoxifen injection
• detected as early as 1 week after the last tamoxifen treatment
• bilobed granulocytes after tamoxifen treatment
• hypersegmented and hyposegmented neutrophils after tamoxifen treatment
• 4 weeks after the last tamoxifen injection
• at 4 weeks after the last tamoxifen injection peripheral blood shows cytological features consistent with myelodysplasia
• increase in the number of lineage-negative ScaI? c-Kit+ myeloid progenitor cells in the spleen and bone marrow as early as 2 weeks after the last tamoxifen treatment
• atypical immature cells with myelomonocytic features detected after tamoxifen treatment
• expansion of the myeloid lineage in the spleen, lymph nodes and bone marrow at 4 weeks after the last tamoxifen injection
• giant platelets detected after tamoxifen treatment
• 4 weeks after the last tamoxifen injection
• in the spleen and bone marrow as early as 2 weeks after the last tamoxifen treatment
• seen in all mice 4 weeks after the last tamoxifen injection
• cells taken from tamoxifen treated mice fail to reconstitute the bone marrow of lethally irradiated congenic wild-type mice
• cultured cells collected 1 month after the last tamoxifen treatment produce fewer colonies and replated cells do not produce well formed colonies

immune system
• neutrophilic inflammation and infiltration of myeloblastic cells after tamoxifen treatment
• elevated total leukocyte numbers at 4 weeks after the last tamoxifen injection
• 4 weeks after the last tamoxifen injection
• bilobed granulocytes after tamoxifen treatment
• hypersegmented and hyposegmented neutrophils after tamoxifen treatment
• 4 weeks after the last tamoxifen injection
• at 4 weeks after the last tamoxifen injection peripheral blood shows cytological features consistent with myelodysplasia
• increase in the number of lineage-negative ScaI? c-Kit+ myeloid progenitor cells in the spleen and bone marrow as early as 2 weeks after the last tamoxifen treatment
• atypical immature cells with myelomonocytic features detected after tamoxifen treatment
• expansion of the myeloid lineage in the spleen, lymph nodes and bone marrow at 4 weeks after the last tamoxifen injection
• seen in all mice 4 weeks after the last tamoxifen injection

homeostasis/metabolism
• microthrombi in the heart after tamoxifen treatment

muscle
• multifocal necrosis after tamoxifen treatment

cardiovascular system
• neutrophilic inflammation and infiltration of myeloblastic cells after tamoxifen treatment

Mouse Models of Human Disease
OMIM IDRef(s)
Myelodysplastic Syndrome; MDS 614286 J:187380